Peptide compounding evidence stays thin for six peptides in HHS policy
Men's Health reviewed the research behind 19 synthetic peptides. For the six now open to pharmacy compounding under an HHS policy, most support comes from animal or cell studies, and none is FDA approved.
WASHINGTON
35 of 36BPC 157 studies in a 2025 review that were animal experiments, as cited by Men's Health
- What's newA Men's Health guide reviewed published research on 19 synthetic peptides, including the six an interim HHS policy lets licensed pharmacies compound. It found most support comes from animal work, cell studies or small uncontrolled human reports.
- Why it mattersPharmacies can now compound BPC 157, TB 500, KPV, MOTS c, Semax and epitalon with a prescription, yet none is FDA approved and human data on safety and effectiveness remain sparse, according to the guide and doctors it quotes.
- What's nextA final FDA decision on listing the six peptides is still pending, and Men's Health says five more peptides face advisory panel review in 2027. Pharmacists must report serious adverse events to the FDA and states.
